for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Becton Dickinson and Co

BDX

Latest Trade

255.30USD

Change

1.82(+0.72%)

Volume

279,127

Today's Range

253.35

 - 

255.60

52 Week Range

219.50

 - 

284.97

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
253.48
Open
254.79
Volume
279,127
3M AVG Volume
29.24
Today's High
255.60
Today's Low
253.35
52 Week High
284.97
52 Week Low
219.50
Shares Out (MIL)
290.82
Market Cap (MIL)
74,068.56
Forward P/E
19.85
Dividend (Yield %)
1.30

Next Event

Q3 2021 Becton Dickinson and Co Earnings Call

Latest Developments

More

Becton, Dickinson And Company Files For Potential Mixed Shelf Offering Size Not Disclosed - SEC Filing

Bd Announces Intent To Spin Off Diabetes Care Business To Enhance Focus On Innovation And Priority Growth Markets

BD Reports Q2 Adjusted EPS $3.19

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Becton Dickinson and Co

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.

Industry

Medical Equipment & Supplies

Contact Info

1 Becton Dr

FRANKLIN LAKES, NJ

07417-1815

United States

+1.201.8476800

http://www.bd.com/

Executive Leadership

Thomas E. Polen

Chairman of the Board, President, Chief Executive Officer, Chief Operating Officer

Christopher R. Reidy

Chief Financial Officer, Executive Vice President, Chief Administrative Officer

David Hickey

President - Life Sciences Segment

Betty D. Larson

Executive Vice President- Human Resources, Chief Human Resources

Simon D. Campion

Executive Vice President and President, BD Interventional Segment

Key Stats

2.16 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

16.0K

2019

17.3K

2020

17.1K

2021(E)

19.4K
EPS (USD)

2018

11.010

2019

11.680

2020

10.200

2021(E)

12.833
Price To Earnings (TTM)
45.33
Price To Sales (TTM)
3.93
Price To Book (MRQ)
2.98
Price To Cash Flow (TTM)
19.30
Total Debt To Equity (MRQ)
71.37
LT Debt To Equity (MRQ)
71.37
Return on Investment (TTM)
3.64
Return on Equity (TTM)
3.16

Latest News

Latest News

Quest Diagnostics sees uptick in COVID-19 testing as Delta variant spreads

U.S. laboratory Quest Diagnostics Inc said on Thursday demand for COVID-19 testing had increased since the end of June as the more infectious Delta variant spreads across the country.

Abbott beats profit estimates as medical device sales rebound

Abbott Laboratories beat quarterly profit estimates on Thursday, driven by a rebound in its non-COVID-19 testing business and sales of its medical devices as vaccinations encouraged Americans to resume non-urgent procedures.

Becton Dickinson's combination test for COVID-19 gets FDA authorization

A molecular test from Becton Dickinson that detects viruses that cause COVID-19 as well as influenza and produces result in 2-3 hours has been given emergency user authorization by the U.S. health regulator, the company said on Friday.

Becton Dickinson's combination test for COVID-19 gets FDA authorization

The U.S. Food and Drug Administration has granted emergency use authorization to a molecular test from Becton Dickinson that can detect viruses that cause COVID-19 as well as influenza and produce results in 2-3 hours, the company said on Friday.

UPDATE 3-Becton Dickinson lifts 2021 profit forecast on robust COVID-19 test demand

Becton Dickinson on Thursday raised its 2021 profit forecast as the medical device maker expects strong demand for its COVID-19 testing kits to extend into the first half of the year.

Becton Dickinson profit surges on demand for COVID-19 tests

Medical technology company Becton Dickinson and Co on Thursday reported a 309% surge in first-quarter profit, fueled by strong demand for its COVID-19 diagnostic tests.

Exclusive: Scarce niche syringes complicate U.S. plan to squeeze more COVID shots from Pfizer vials

The U.S. government's effort to squeeze more doses from Pfizer Inc's COVID-19 vaccine vials is spurring unanticipated demand for specialized syringes that the world's largest syringe supplier says exceeds existing capacity.

Becton Dickinson sees first-quarter revenue above estimates on demand for COVID-19 tests

Becton Dickinson and Co on Tuesday forecast first-quarter revenue above Wall Street estimates due to strong demand for its COVID-19 diagnostic tests.

Becton Dickinson to invest $1.2 bln to boost syringe supply

Becton Dickinson and Co will invest about $1.2 billion to boost syringe production, the world's largest needle maker said on Wednesday, as the United States inches closer to making a COVID-19 vaccine available to its people.

Musk questions coronavirus tests, saying they gave opposite results on same day

Tesla Inc <TSLA.O> Chief Executive Officer Elon Musk questioned the accuracy of COVID-19 tests on Thursday after claiming that results showed he tested positive twice and then negative twice all on the same day.

BRIEF-Becton Dickinson Says Aware Of The Tweet By Elon Musk And Are Reaching Out To Learn More, Consistent With Our Quality Management Process - Tweet

* BECTON DICKINSON SAYS AWARE OF THE TWEET BY ELON MUSK AND ARE REACHING OUT TO LEARN MORE, CONSISTENT WITH OUR QUALITY MANAGEMENT PROCESS - TWEET

Becton Dickinson sees COVID-19 test sales of up to $1.5 billion after profit beat

Medical device maker Becton Dickinson and Co <BDX.N> said on Thursday it expects as much as $1.5 billion in sales from its COVID-19 diagnostic test next year, after reporting a quarterly profit that beat Wall Street estimates.

Becton Dickinson posts 16% fall in quarterly profit

Becton Dickinson and Co on Thursday posted a 16% fall in fourth-quarter profit, as the medical technology company was hurt by patients deferring discretionary procedures due to the COVID-19 pandemic.

UPDATE 1-Nevada's ban on Quidel and Becton Dickinson COVID-19 tests violates law -HHS official

Nevada's recent ban on the use of Quidel Corp's Sofia and Becton Dickinson and Co's Veritor point-of-care antigen tests for COVID-19 in long-term care facilities violates federal law, a U.S. government official said on Friday.

Nevada's prohibition of Quidel, Becton Dickinson's COVID-19 tests violates law: HHS official

U.S. state of Nevada's recent ban on the use of Quidel Corp's Sofia and Becton Dickinson and Co's (BD) Veritor point of care antigen tests in long-term care facilities violates federal law, a U.S. government official said on Friday.

Becton Dickinson says COVID-19 test kit meets requirements for Europe launch

U.S. medical device maker Becton Dickinson and Co said on Wednesday its COVID-19 antigen test kit met the requirements for a launch in Europe.

Becton Dickinson reaches $60 million settlement over pelvic mesh devices

Becton Dickinson and Co agreed to pay $60 million to resolve allegations by the attorneys general of 48 U.S. states and Washington D.C. that its CR Bard unit concealed the risks of its now-discontinued transvaginal pelvic mesh devices.

Becton Dickinson reaches $60 million settlement over pelvic mesh products

Becton Dickinson and Co said on Thursday it has reached a $60 million settlement with the attorneys general of 48 U.S. states and Washington, D.C. to settle litigation related to discontinued pelvic mesh products.

Becton Dickinson reaches $60 mln settlement over pelvic mesh products

Becton Dickinson and Co said on Thursday it has reached a $60 million settlement with the attorneys general of 48 U.S. states and Washington, D.C. to settle litigation related to discontinued pelvic mesh products.

NY sues Becton Dickinson unit over surgical mesh devices, consent judgment expected

New York's attorney general on Thursday filed a lawsuit accusing Becton Dickinson and Co's CR Bard unit of concealing the risks of surgical mesh devices.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up